Hosted on MSN5d
Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer
Amgen AMGN announced that the FDA has approved its KRAS inhibitor, Lumakras (sotorasib), in combination with its anti-EGFR ...
Pharm Exec5d
FDA Approves Amgen’s Lumakras Plus Vectibix for KRAS G12C-Mutated Metastatic Colorectal Cancer
Approval is based on data from the Phase III CodeBreaK 300 trial, which demonstrated that treatment with Lumakras and ...
GlobalData on MSN5d
FDA approves Amgen’s combo therapy for colorectal cancer
Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA for treating KRAS G12C-mutated mCRC.
FiercePharma8d
AstraZeneca's Calquence and Amgen's Lumakras clinch FDA label expansions
Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...
Amgen wins FDA nod for Lumakras as a drug combo for colorectal cancer
Amgen (AMGN) stock in focus as U.S. approval for its lung cancer drug expands for metastatic colorectal cancer. Read more ...
pharmaphorum8d
Amgen picks up key colorectal cancer okay for KRAS drug
Amgen's first-to-market KRAS inhibitor Lumakras has so far failed to live up to once-lofty sales expectations, but a new FDA approval could lend momentum to its growth. The US regulator has ...
ENDPOINTS NEWS8d
Af­ter three-month de­lay, Am­gen’s Lumakras clinch­es FDA green light in col­orec­tal can­cer
FDA approves Amgen's Lumakras with Vectibix for metastatic colorectal cancer with KRAS G12C mutation, based on Phase 3 ...
PMLiVE8d
Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer
Lumakras (sotorasib) and Vectibix (panitumumab) have been authorised for use in adults with KRAS G12C-mutated metastatic ...
US FDA approves Amgen's colorectal cancer therapy
The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...